{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000129","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.730044+00:00","generated_at":"2026-06-10T10:29:28.440206+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kiora Pharma appoints Praveen Tyle as Chairman; Paul Chaney retires after 17 years","bullets":["Paul Chaney resigned as Chairman and Board member effective Sept 20, 2023; no disagreement cited.","Praveen Tyle, PhD, appointed Chairman effective same date; also serves as director.","Erin Parsons appointed Chair of Compensation Committee; Carmine Stengone joins Audit and Nominating Committees.","Tyle to help guide development of KIO-301 for retinitis pigmentosa and other inherited retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000129","json":"https://secwatch.observer/filing/0001372514-23-000129.json","markdown":"https://secwatch.observer/filing/0001372514-23-000129.md","text":"https://secwatch.observer/filing/0001372514-23-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000129/0001372514-23-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000129/kprx-20230920.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:29:28.440206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad9337ce1a","claim":"Paul Chaney resigned as Chairman at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"On September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000129/0001372514-23-000129-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"},{"claim_id":"d9a4db18f0","claim":"Praveen Tyle was appointed as Chairman at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000129/0001372514-23-000129-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}